Effect of fibrates on glycemic parameters

A systematic review and meta-analysis of randomized placebo-controlled trials

Luis E. Simental-Mendía, Mario Simental-Mendía, Adriana Sánchez-García, Maciej Banach, Stephen Atkin, Antonio M. Gotto, Amirhossein Sahebkar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims: The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of fibrates on glycemic parameters. Materials and methods: Only randomized placebo-controlled trials investigating the impact of fibrate treatment on glucose homeostasis markers were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (from inception to April 11, 2017). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on glycemic parameters. Results: This meta-analysis of data from 22 randomized placebo-controlled clinical trials involving a total of 11,402 subjects showed that fibrate therapy significantly decreased fasting plasma glucose (WMD: -0.28 mmol/L, 95% CI: -0.42, -0.14, p < 0.001), insulin levels (WMD: -3.87 pmol/L, 95% CI: -4.97, -2.78, p < 0.001) and insulin resistance (HOMA-IR, WMD: -1.09, 95% CI: -1.71, -0.47, p = 0.001), but with no effect on HbA1c (WMD: 0.01%, 95% CI: -0.18, 0.19, p = 0.955). All analyses were robust in the leave-one-out sensitivity analysis except for insulin levels that showed a non-significant result (WMD: -0.84 pmol/L, 95% CI: -6.36, 4.68, p = 0.766) following omission of one of the included trials. Conclusion: This meta-analysis has shown that fibrate treatment significantly decreases fasting plasma glucose, insulin levels, and HOMA-IR indicating additional clinical therapeutic benefits.

Original languageEnglish
JournalPharmacological Research
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Fibric Acids
Meta-Analysis
Randomized Controlled Trials
Placebos
Insulin
Glucose
Fasting
Therapeutics
PubMed
Insulin Resistance
Homeostasis
Databases

Keywords

  • Fibrates
  • Glucose
  • Insulin
  • Insulin resistance
  • Meta-analysis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Simental-Mendía, L. E., Simental-Mendía, M., Sánchez-García, A., Banach, M., Atkin, S., Gotto, A. M., & Sahebkar, A. (Accepted/In press). Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research. https://doi.org/10.1016/j.phrs.2017.12.030

Effect of fibrates on glycemic parameters : A systematic review and meta-analysis of randomized placebo-controlled trials. / Simental-Mendía, Luis E.; Simental-Mendía, Mario; Sánchez-García, Adriana; Banach, Maciej; Atkin, Stephen; Gotto, Antonio M.; Sahebkar, Amirhossein.

In: Pharmacological Research, 01.01.2018.

Research output: Contribution to journalArticle

Simental-Mendía, Luis E. ; Simental-Mendía, Mario ; Sánchez-García, Adriana ; Banach, Maciej ; Atkin, Stephen ; Gotto, Antonio M. ; Sahebkar, Amirhossein. / Effect of fibrates on glycemic parameters : A systematic review and meta-analysis of randomized placebo-controlled trials. In: Pharmacological Research. 2018.
@article{c8be0abb9d8748dea6880fdbf44e8a49,
title = "Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials",
abstract = "Aims: The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of fibrates on glycemic parameters. Materials and methods: Only randomized placebo-controlled trials investigating the impact of fibrate treatment on glucose homeostasis markers were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (from inception to April 11, 2017). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on glycemic parameters. Results: This meta-analysis of data from 22 randomized placebo-controlled clinical trials involving a total of 11,402 subjects showed that fibrate therapy significantly decreased fasting plasma glucose (WMD: -0.28 mmol/L, 95{\%} CI: -0.42, -0.14, p < 0.001), insulin levels (WMD: -3.87 pmol/L, 95{\%} CI: -4.97, -2.78, p < 0.001) and insulin resistance (HOMA-IR, WMD: -1.09, 95{\%} CI: -1.71, -0.47, p = 0.001), but with no effect on HbA1c (WMD: 0.01{\%}, 95{\%} CI: -0.18, 0.19, p = 0.955). All analyses were robust in the leave-one-out sensitivity analysis except for insulin levels that showed a non-significant result (WMD: -0.84 pmol/L, 95{\%} CI: -6.36, 4.68, p = 0.766) following omission of one of the included trials. Conclusion: This meta-analysis has shown that fibrate treatment significantly decreases fasting plasma glucose, insulin levels, and HOMA-IR indicating additional clinical therapeutic benefits.",
keywords = "Fibrates, Glucose, Insulin, Insulin resistance, Meta-analysis",
author = "Simental-Mend{\'i}a, {Luis E.} and Mario Simental-Mend{\'i}a and Adriana S{\'a}nchez-Garc{\'i}a and Maciej Banach and Stephen Atkin and Gotto, {Antonio M.} and Amirhossein Sahebkar",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.phrs.2017.12.030",
language = "English",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Effect of fibrates on glycemic parameters

T2 - A systematic review and meta-analysis of randomized placebo-controlled trials

AU - Simental-Mendía, Luis E.

AU - Simental-Mendía, Mario

AU - Sánchez-García, Adriana

AU - Banach, Maciej

AU - Atkin, Stephen

AU - Gotto, Antonio M.

AU - Sahebkar, Amirhossein

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of fibrates on glycemic parameters. Materials and methods: Only randomized placebo-controlled trials investigating the impact of fibrate treatment on glucose homeostasis markers were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (from inception to April 11, 2017). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on glycemic parameters. Results: This meta-analysis of data from 22 randomized placebo-controlled clinical trials involving a total of 11,402 subjects showed that fibrate therapy significantly decreased fasting plasma glucose (WMD: -0.28 mmol/L, 95% CI: -0.42, -0.14, p < 0.001), insulin levels (WMD: -3.87 pmol/L, 95% CI: -4.97, -2.78, p < 0.001) and insulin resistance (HOMA-IR, WMD: -1.09, 95% CI: -1.71, -0.47, p = 0.001), but with no effect on HbA1c (WMD: 0.01%, 95% CI: -0.18, 0.19, p = 0.955). All analyses were robust in the leave-one-out sensitivity analysis except for insulin levels that showed a non-significant result (WMD: -0.84 pmol/L, 95% CI: -6.36, 4.68, p = 0.766) following omission of one of the included trials. Conclusion: This meta-analysis has shown that fibrate treatment significantly decreases fasting plasma glucose, insulin levels, and HOMA-IR indicating additional clinical therapeutic benefits.

AB - Aims: The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of fibrates on glycemic parameters. Materials and methods: Only randomized placebo-controlled trials investigating the impact of fibrate treatment on glucose homeostasis markers were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (from inception to April 11, 2017). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on glycemic parameters. Results: This meta-analysis of data from 22 randomized placebo-controlled clinical trials involving a total of 11,402 subjects showed that fibrate therapy significantly decreased fasting plasma glucose (WMD: -0.28 mmol/L, 95% CI: -0.42, -0.14, p < 0.001), insulin levels (WMD: -3.87 pmol/L, 95% CI: -4.97, -2.78, p < 0.001) and insulin resistance (HOMA-IR, WMD: -1.09, 95% CI: -1.71, -0.47, p = 0.001), but with no effect on HbA1c (WMD: 0.01%, 95% CI: -0.18, 0.19, p = 0.955). All analyses were robust in the leave-one-out sensitivity analysis except for insulin levels that showed a non-significant result (WMD: -0.84 pmol/L, 95% CI: -6.36, 4.68, p = 0.766) following omission of one of the included trials. Conclusion: This meta-analysis has shown that fibrate treatment significantly decreases fasting plasma glucose, insulin levels, and HOMA-IR indicating additional clinical therapeutic benefits.

KW - Fibrates

KW - Glucose

KW - Insulin

KW - Insulin resistance

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85039916001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039916001&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2017.12.030

DO - 10.1016/j.phrs.2017.12.030

M3 - Article

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -